Current Challenges for the Early Detection of Alzheimer’s Disease: Brain Imaging and CSF Studies|RISS 상세보기

다국어 초록 (Multilingual Abstract)

The development of prevention therapies for Alzheimer’s disease (AD) would greatly benefit
from biomarkers that are sensitive to the subtle brain changes that occur in the preclinical stage
of the disease. Reductions in the cerebral metabolic rate of glucose (CMRglc), a measure of
neuronal function, have proven to be a promising tool in the early diagnosis of AD. In vivo
brain 2-[
18
F]fluoro-2-Deoxy-D-glucose-positron emission tomography (FDG-PET) imaging demonstrates consistent and progressive CMRglc reductions in AD patients, the extent and topography of which correlate with symptom severity. There is increasing evidence that hypometabolism appears during the preclinical stages of AD and can predict decline years before
the onset of symptoms. This review will give an overview of FDG-PET results in individuals at
risk for developing dementia, including: presymptomatic individuals carrying mutations responsible for early-onset familial AD; patients with Mild Cognitive Impairment (MCI), often a
prodrome to late-onset sporadic AD; non-demented carriers of the Apolipoprotein E (ApoE) ε4
allele, a strong genetic risk factor for late-onset AD; cognitively normal subjects with a family
history of AD; subjects with subjective memory complaints; and normal elderly followed longitudinally until they expressed the clinical symptoms and received post-mortem confirmation of
AD. Finally, we will discuss the potential to combine different PET tracers and CSF markers of
pathology to improve the early detection of AD.

번역하기

참고문헌 (Reference)

1 Consensus report of the Working Group on, "“Molecular and Biochemical Markers of Alzheimer’s Disease”. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging" 19 : 109-116, 1998

2 Mintun MA, "[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease" 67 : 446-452, 2006

3 Kemppainen NM, "Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease" 67 : 1575-1580, 2006

4 Mosconi L, "Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer’s disease using FDG-PET" 33 : 210-221, 2006

5 Silverman JM, "Variability of familial risk of Alzheimer disease across the late life span" 62 : 565-573, 2005

6 den Heijer T, "Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people" 63 : 57-62, 2006

7 Klunk WE, "Twoyear follow-up of amyloid deposition in patients with Alzheimer’s disease" 129 : 2805-2807, 2006

8 Hesse C, "Transient increase in total tau but not phosphotau in human cerebrospinal fluid after acute stroke" 297 : 187-190, 2001

9 Tapiola T, "Three-year follow-up of cerebrospinal fluid tau, B-amyloid 42 and 40 concentrations in Alzheimer’s disease" 280 : 119-122, 2000

10 Attwell D, "The neural basis of functional brain imaging signals" 25 : 621-625, 2002